Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 1, 2011, Pages 9-15

  Sajadi, Mohammad M ^a,c   Guan, Yongjun ^a   Devico, Anthony L ^a   Seaman, Michael S ^b   Hossain, Mian ^a   Lewis, George K ^a   Redfield, Robert R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NONE   (United States)

Author keywords

broadly neutralizing antibody; elite controller; HIV; HIV RNA; natural viral suppressor; neutralizing activity

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NEUTRALIZING ANTIBODY; VIRUS RNA;

ADULT; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

ADULT; ANTIBODIES, NEUTRALIZING; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, HUMORAL; LOGISTIC MODELS; MALE; MIDDLE AGED; RNA, VIRAL; YOUNG ADULT;

EID: 79955024433     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182100c1b     Document Type: Article

References (20)

1. Pitisuttithum P, Berman PW, Phonrat B, et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr. 2004;37:1160-1165. Erratum in: J Acquir Immune Defic Syndr. 2004;37:1669. (Pubitemid 39166651)
2. Bailey JR, Lassen KG, Yang HC, et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol. 2006;80:4758-4770.
3. Sajadi MM, Heredia A, Le N, et al. HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS. 2007;21: 517-519.
4. Sajadi MM, Constantine NT, Mann DL, et al. Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr. 2009;50:403-408. PMID: 19214118.
5. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79: 10108-10125. (Pubitemid 41098552)
6. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory b cells in HIV-infected individuals. Nature. 2009;458:636-640.
7. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197:563-571. (Pubitemid 351321534)
8. Guan Y, Sajadi MM, Kamin-Lewis R, et al. Humoral immunity against conserved epitopes of the HIV-1 envelope protein archived in memory B cells in natural viral suppressors: discordance with plasma antibodies. Proc Natl Acad Sci USA. 2009;106:3952-3957. PMID: 19225108.
9. Pilgrim AK, Pantaleo G, Cohen OJ, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis. 1997;176:924-932. (Pubitemid 27411034)
10. Cecilia D, Kleeberger C, Muñoz A, et al. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis. 1999;179:1365-1374. (Pubitemid 29246584)
11. Zhang YJ, Fracasso C, Fiore JR, et al. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis. 1997;176:1180-1187. (Pubitemid 27460982)
12. Barker E, Mackewicz CE, Reyes-Terán G, et al. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood. 1998;92:3105-3114. (Pubitemid 28492316)
13. Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses. 1996; 12:585-592. (Pubitemid 26120291)
14. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory b cells in HIV-infected individuals. Nature. 2009;458:636-640.
15. Doria-Rose NA, Klein RM, Manion MM, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol. 2009;83:188-199. E-pub October 15, 2008.
16. Sather DN, Armann J, Ching LK, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol. 2009;83:757-769. E-pub November 5, 2008. Erratum in: J Virol. 2009;83:4713-4715. PMID: 18987148.
17. Wong MT, Warren RQ, Anderson SA, et al. Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjects. J Infect Dis. 1993;168:1523-1527. (Pubitemid 23344917)
18. Piantadosi A, Panteleeff D, Blish CA, et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol. 2009;83:10269-10274. E-pub July 29, 2009. PMID: 19640996.
19. Deeks SG, Schweighardt B, Wrin T, et al. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol. 2006;80:6155-6164. (Pubitemid 43849193)
20. Rodriguez SK, Sarr AD, MacNeil A, et al. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. J Virol. 2007;81:5331-5338. E-pub February 14, 2007. PMID: 17301136. (Pubitemid 46744442)